Company intelligence / Profile preview
Hoechst
Frankfurt am Main-Höchst, Hesse, Germanyindustriepark-hoechst.com ↗
- Ownership
- Private
- Employees
- ~100000
- Development stage
- Commercial
01
Overview
At the time of its merger into Aventis in late '90s, Hoechst had a broad portfolio with major marketed drugs and over sixty projects in development targeting cardiovascular disease, cancer, asthma/allergy, diabetes and CNS disorders. Its legacy includes pioneering work on analgesics and antibiotics.
- Therapeutic areas
- OncologyEndocrinologyImmunologyCardiovascularNeurologyInfectious Diseases
- Modalities
- Small moleculeBiologic
- Industry
- Pharma
02
Drug pipeline
26 assets25 more assets in the full pipeline.
Request access →03
Partnerships
Rhône-Poulenc S.A.Handok Pharmaceuticals
Beyond the preview
Go deeper on Hoechst.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hoechst.